- Home
- Publications
- Publication Search
- Publication Details
Title
RdRp inhibitors and COVID-19: Is molnupiravir a good option?
Authors
Keywords
SARS-CoV-2, Small molecule drug, RdRp inhibitors, Molnupiravir, Clinical trials
Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 146, Issue -, Pages 112517
Publisher
Elsevier BV
Online
2021-12-09
DOI
10.1016/j.biopha.2021.112517
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2
- (2021) Wendy P. Painter et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of ribavirin and interferon-α therapy for hospitalized patients with COVID-19: A multicenter, retrospective cohort study
- (2021) Hui Li et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
- (2021) Angela Wahl et al. NATURE
- β-D-N 4-hydroxycytidine (NHC) Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells
- (2021) Shuntai Zhou et al. JOURNAL OF INFECTIOUS DISEASES
- Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
- (2021) Kyle Rosenke et al. Nature Communications
- A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents
- (2021) Thuc Nguyen Dan Do et al. ANTIVIRAL RESEARCH
- The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines
- (2021) Mehrdad Mohammadi et al. Brazilian Journal of Infectious Diseases
- Acute and post-acute phase of COVID-19: Analyzing expression patterns of miRNA-29a-3p, 146a-3p, 155-5p, and let-7b-3p in PBMC
- (2021) Tahereh Donyavi et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Potential SARS-CoV-2 vaccines: Concept, progress, and challenges
- (2021) Seyede Atefe Hosseini et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
- (2021) Saye H Khoo et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model
- (2021) Rana Abdelnabi et al. JOURNAL OF INFECTIOUS DISEASES
- Covid-19: UK becomes first country to authorise antiviral molnupiravir
- (2021) Elisabeth Mahase BMJ-British Medical Journal
- Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19
- (2021) George R Painter et al. Current Opinion in Virology
- Molnupiravir in COVID-19: A systematic review of literature
- (2021) Awadhesh Kumar Singh et al. Diabetes & Metabolic Syndrome-Clinical Research & Reviews
- Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China
- (2020) Aiping Wu et al. Cell Host & Microbe
- Coronavirus Infections—More Than Just the Common Cold
- (2020) Catharine I. Paules et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China
- (2020) Dawei Wang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus
- (2020) Calvin J Gordon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS
- (2020) Yushun Wan et al. JOURNAL OF VIROLOGY
- Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
- (2020) Nanshan Chen et al. LANCET
- First Case of 2019 Novel Coronavirus in the United States
- (2020) Michelle L. Holshue et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Novel Coronavirus from Patients with Pneumonia in China, 2019
- (2020) Na Zhu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
- (2020) Kimiyasu Shiraki et al. PHARMACOLOGY & THERAPEUTICS
- Pathological findings of COVID-19 associated with acute respiratory distress syndrome
- (2020) Zhe Xu et al. Lancet Respiratory Medicine
- Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
- (2020) Canrong Wu et al. Acta Pharmaceutica Sinica B
- Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools
- (2020) Yajing Fu et al. VIROLOGICA SINICA
- Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
- (2020) Daniel Blanco-Melo et al. CELL
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection
- (2020) Yin‐Xiao Du et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Isolation and Full-Length Genome Characterization of SARS-CoV-2 from COVID-19 Cases in Northern Italy
- (2020) Danilo Licastro et al. JOURNAL OF VIROLOGY
- Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China
- (2020) Hua Su et al. KIDNEY INTERNATIONAL
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
- (2020) Yeming Wang et al. LANCET
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
- (2020) Jason D. Goldman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
- (2020) Bin Cao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structure of the RNA-dependent RNA polymerase from COVID-19 virus
- (2020) Yan Gao et al. SCIENCE
- An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
- (2020) Timothy P. Sheahan et al. Science Translational Medicine
- Understanding pathways to death in patients with COVID-19
- (2020) Jean-Louis Vincent et al. Lancet Respiratory Medicine
- Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
- (2020) Lei Fang et al. Lancet Respiratory Medicine
- Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19
- (2020) Richard T. Eastman et al. ACS Central Science
- Potential role for nitazoxanide in treating SARS-CoV-2 infection
- (2020) Paulo Ricardo Martins-Filho et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- Host-targeted nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir-resistant influenza viruses in vitro or in vivo when used in combination with oseltamivir
- (2020) Danielle Tilmanis et al. ANTIVIRAL RESEARCH
- AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
- (2020) Andrey A Ivashchenko et al. CLINICAL INFECTIOUS DISEASES
- A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19
- (2020) Andrea Cortegiani et al. JOURNAL OF CRITICAL CARE
- Clinical and virological data of the first cases of COVID-19 in Europe: a case series
- (2020) Francois-Xavier Lescure et al. LANCET INFECTIOUS DISEASES
- Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
- (2020) Brandi N. Williamson et al. NATURE
- Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management
- (2020) Mina T. Kelleni PHARMACOLOGICAL RESEARCH
- A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19
- (2020) Seyed MohammadReza Hashemian et al. Drug Design Development and Therapy
- Recent insights for the emerging COVID-19: drug discovery, therapeutic options and vaccine development
- (2020) Yuefei Zhu et al. Asian Journal of Pharmaceutical Sciences
- Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses
- (2020) E. Susan Amirian et al. One Health
- Proteolytic Cleavage of the SARS-CoV-2 Spike Protein and the Role of the Novel S1/S2 Site
- (2020) Javier A. Jaimes et al. iScience
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
- (2020) Christoph D. Spinner et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pathophysiology and treatment strategies for COVID-19
- (2020) Manoj Kumar et al. Journal of Translational Medicine
- Remdesivir Approved to Treat COVID-19 Amid Controversy
- (2020) Diane S. Aschenbrenner AMERICAN JOURNAL OF NURSING
- A review on favipiravir: the properties, function, and usefulness to treat COVID-19
- (2020) Seyed MohammadReza Hashemian et al. Expert Review of Anti-Infective Therapy
- Synergistic and Antagonistic Drug Combinations against SARS-CoV-2
- (2020) Tesia Bobrowski et al. MOLECULAR THERAPY
- Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge
- (2020) Francesca Picarazzi et al. MOLECULES
- Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
- (2020) Robert M. Cox et al. Nature Microbiology
- Coronavirus envelope protein: current knowledge
- (2019) Dewald Schoeman et al. Virology Journal
- Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir
- (2019) Egor Tchesnokov et al. Viruses-Basel
- Evaluation of nitazoxanide as a novel drug for the treatment of acute and chronic toxoplasmosis
- (2019) Samy Ibrahim El-Kowrany et al. ACTA TROPICA
- Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase
- (2019) Ariane J. Brown et al. ANTIVIRAL RESEARCH
- Analysis of the Potential for N4-Hydroxycytidine to Inhibit Mitochondrial Replication and Function
- (2019) Zachary M. Sticher et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection
- (2019) George R. Painter et al. ANTIVIRAL RESEARCH
- Small-Molecule Antiviral β-D-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance
- (2019) Maria L. Agostini et al. JOURNAL OF VIROLOGY
- Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia
- (2019) Mart Toots et al. Science Translational Medicine
- Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model
- (2019) Mart Toots et al. Translational Research
- Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses
- (2018) Jeong-Joong Yoon et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Favipiravir as a potential countermeasure against neglected and emerging RNA viruses
- (2018) Leen Delang et al. ANTIVIRAL RESEARCH
- Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase
- (2018) Paul C. Jordan et al. PLoS Pathogens
- In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit
- (2018) Takeshi Noshi et al. ANTIVIRAL RESEARCH
- Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
- (2017) Yousuke FURUTA et al. PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
- (2017) Timothy P. Sheahan et al. Science Translational Medicine
- Origin and Evolution of RNA-Dependent RNA Polymerase
- (2017) Savio T. de Farias et al. Frontiers in Genetics
- Approved Antiviral Drugs over the Past 50 Years
- (2016) Erik De Clercq et al. CLINICAL MICROBIOLOGY REVIEWS
- Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
- (2016) Travis K. Warren et al. NATURE
- Coronaviruses — drug discovery and therapeutic options
- (2016) Alimuddin Zumla et al. NATURE REVIEWS DRUG DISCOVERY
- IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study
- (2015) Sarah Shalhoub et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis
- (2015) Kentaro Yamada et al. JOURNAL OF INFECTIOUS DISEASES
- A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence
- (2015) Vineet D Menachery et al. NATURE MEDICINE
- Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance
- (2015) Auda Eltahla et al. Viruses-Basel
- A Crystal Structure of the Dengue Virus NS5 Protein Reveals a Novel Inter-domain Interface Essential for Protein Flexibility and Virus Replication
- (2015) Yongqian Zhao et al. PLoS Pathogens
- Nitazoxanide: A first-in-class broad-spectrum antiviral agent
- (2014) Jean-François Rossignol ANTIVIRAL RESEARCH
- Action of nitroheterocyclic drugs against Clostridium difficile
- (2014) Manish Kumar et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study
- (2014) Jaffar A. Al-Tawfiq et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study
- (2014) Ali S Omrani et al. LANCET INFECTIOUS DISEASES
- Evolution of Tertiary Structure of Viral RNA Dependent Polymerases
- (2014) Jiří Černý et al. PLoS One
- Emerging Viral Diseases: Confronting Threats with New Technologies
- (2014) H. D. Marston et al. Science Translational Medicine
- Favipiravir (T-705), a novel viral RNA polymerase inhibitor
- (2013) Yousuke Furuta et al. ANTIVIRAL RESEARCH
- T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses In Vitro
- (2013) T. Baranovich et al. JOURNAL OF VIROLOGY
- Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques
- (2013) Darryl Falzarano et al. NATURE MEDICINE
- The Ambiguous Base-Pairing and High Substrate Efficiency of T-705 (Favipiravir) Ribofuranosyl 5′-Triphosphate towards Influenza A Virus Polymerase
- (2013) Zhinan Jin et al. PLoS One
- Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin
- (2013) Darryl Falzarano et al. Scientific Reports
- Coronaviruses Lacking Exoribonuclease Activity Are Susceptible to Lethal Mutagenesis: Evidence for Proofreading and Potential Therapeutics
- (2013) Everett Clinton Smith et al. PLoS Pathogens
- Biochemical characterization of a recombinant SARS coronavirus nsp12 RNA-dependent RNA polymerase capable of copying viral RNA templates
- (2012) Dae-Gyun Ahn et al. ARCHIVES OF VIROLOGY
- Antiviral Activity of Substituted Salicylanilides - A Review
- (2011) M. Kratky et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Genomic Characterization of Severe Acute Respiratory Syndrome-Related Coronavirus in European Bats and Classification of Coronaviruses Based on Partial RNA-Dependent RNA Polymerase Gene Sequences
- (2010) J. F. Drexler et al. JOURNAL OF VIROLOGY
- The RNA polymerase activity of SARS-coronavirus nsp12 is primer dependent
- (2009) Aartjan J. W. te Velthuis et al. NUCLEIC ACIDS RESEARCH
- The flavivirus polymerase as a target for drug discovery
- (2008) Hélène Malet et al. ANTIVIRAL RESEARCH
- Cell-based assays to identify inhibitors of viral disease
- (2008) Neil Green et al. Expert Opinion on Drug Discovery
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now